Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC belimumab plus standard therapy in pediatric SLE
2023-509413-37-00Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoints: Observed belimumab concentrations at Week 12 and Steady-state PK parameters: Cavg (AUC), Cmax, Cmin. Started Jan 2020; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-509413-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509413-37-00.